Market Overview

UPDATE: Deutsche Bank Raises PT to $95 on Gilead Sciences on Latest Data

Related GILD
Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space
Watch These 5 Huge Put Purchases In Monday Trade
Gilead NASH Drug 'Active And Promising,' But Lagging Intercept (Investor's Business Daily)

Deutsche Bank reiterated its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $75 to $95.

Deutsche Bank said, "At the liver meeting today, Bristol ns5a and GILD nuke showed 100pct SVR with or without ribavirin, in patients that showed up for follow-up. So far 68/82 patients are at SVR12 timeframe and it was noted all 68 were undetectable. While Bristol and Abbott also have regimens with high cure rates, they require more pills (3 drug DAA) and likely will require ribavirin."

Gilead Sciences closed at $73.92 on Monday.

Latest Ratings for GILD

Oct 2016JefferiesMaintainsBuy
Oct 2016RBC CapitalMaintainsOutperform
Sep 2016Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!